Drug design and development can be facilitated to target a specific cancer cell. This type of technology can be used when a cancer expresses a specific marker, gene, or characteristic that differentiates it from other, non-cancer cells, in the same body. Direct targeting of a cancer cell can lead to therapies that elicit fewer side effects and better anti-tumor efficacy.
The long term goal of our collaborative effort is to bring precision medicine to the practice of veterinary oncology, using the wealth of genomic data gathered in human cancers as a roadmap....
This talk will review successful efforts at Washington University to employ novel reagents and informatics to the problem of rare allele detection. I will discuss a published bakeoff of in si...
The development of automated DNA sequencers utilizing Sanger sequencing and capillary electrophoresis made it possible to develop the first draft sequences of the human genome. The cost of do...
In this presentation, Dr. Kothari will provide an overview of the Precision Medicine Initiative from NIH and how NGS technologies have helped the researchers to look deep inside the human tra...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
The NIH put Precision Medicine on the map as a revolutionary way to manage disease, delivering the right treatment, to the right patient, at the right time. But what does Precision Medicine r...
Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations. Subclones can have unique phenotypes that influence disea...
Inherited disorders affect millions of people globally. These diseases significantly impact lives of patients and their families, and in addition, also results in substantial socio-economic i...
DATE: May 21, 2019TIMEL 7:00am PT, 10:00am ET Human T cells are central effectors of immunity and cancer immunotherapy. CRISPR-based functional studies in T cells could prioriti...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
The lung is a highly complex organ, comprised of more than 40 cell types that are responsible for various important functions, the lung’s complexity contributes to the subsequent challe...
The most recently developed genome editing system, CRISPR-Cas9 has greater inherent flexibility than prior programmable nuclease platforms. Because of its simplicity and efficacy, this techno...
When looking to answer complex biological questions, using in vitro techniques, you want the model that best reflects the in vivo condition. For decades two-dimensional cell culture has...
To ensure the immune system’s balance between the recognition of non-self and the prevention of autoimmunity, the activity of immune cells needs to be strictly controlled. During the pr...
DATE: August 7, 2018TIME: 08:00AM PDT, 11:00AM EDTWe are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is drivi...
The introduction of targeted therapies into the clinical management of lung adenocarcinoma has had a massive impact on patient care. Multiple driver mutations are now druggable and treatments...
DATE: October 24, 2017TIME: 09:00am PDT, 12:00pm EDTDoes your work involve disease models? Do you have a need to introduce specific genomic changes in the cells of your choice? Do you w...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
Addressing the antibody reproducibility crisis: A panel discussion with key scientific leaders Reproducibility and antibody validation standards are two significant challenges f...
EVENT DETAILS:DATE: May 16, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science our first commit...
Much has been made in the popular press about importance of our "genes" in everything from our weight, intelligence, and our risk of disease. While there is a scientific basis...
The long term goal of our collaborative effort is to bring precision medicine to the practice of veterinary oncology, using the wealth of genomic data gathered in human cancers as a roadmap....
This talk will review successful efforts at Washington University to employ novel reagents and informatics to the problem of rare allele detection. I will discuss a published bakeoff of in si...
The development of automated DNA sequencers utilizing Sanger sequencing and capillary electrophoresis made it possible to develop the first draft sequences of the human genome. The cost of do...
In this presentation, Dr. Kothari will provide an overview of the Precision Medicine Initiative from NIH and how NGS technologies have helped the researchers to look deep inside the human tra...
Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation l...
The NIH put Precision Medicine on the map as a revolutionary way to manage disease, delivering the right treatment, to the right patient, at the right time. But what does Precision Medicine r...
Virtually all tumors are genetically heterogeneous, containing subclonal populations of cells that are defined by distinct mutations. Subclones can have unique phenotypes that influence disea...
Inherited disorders affect millions of people globally. These diseases significantly impact lives of patients and their families, and in addition, also results in substantial socio-economic i...
DATE: May 21, 2019TIMEL 7:00am PT, 10:00am ET Human T cells are central effectors of immunity and cancer immunotherapy. CRISPR-based functional studies in T cells could prioriti...
Recent clinical successes in cancer genome-inspired personalized medicine have been a major breakthrough in drug discovery. However, 98% of the patients have an incomplete therapeutic respons...
The lung is a highly complex organ, comprised of more than 40 cell types that are responsible for various important functions, the lung’s complexity contributes to the subsequent challe...
The most recently developed genome editing system, CRISPR-Cas9 has greater inherent flexibility than prior programmable nuclease platforms. Because of its simplicity and efficacy, this techno...
When looking to answer complex biological questions, using in vitro techniques, you want the model that best reflects the in vivo condition. For decades two-dimensional cell culture has...
To ensure the immune system’s balance between the recognition of non-self and the prevention of autoimmunity, the activity of immune cells needs to be strictly controlled. During the pr...
DATE: August 7, 2018TIME: 08:00AM PDT, 11:00AM EDTWe are currently at an exciting precipice in clinical oncology management, where an increased rate of biomarker identification is drivi...
The introduction of targeted therapies into the clinical management of lung adenocarcinoma has had a massive impact on patient care. Multiple driver mutations are now druggable and treatments...
DATE: October 24, 2017TIME: 09:00am PDT, 12:00pm EDTDoes your work involve disease models? Do you have a need to introduce specific genomic changes in the cells of your choice? Do you w...
DATE: October 17, 2017TIME: 08:00am PDT, 11:00am EDTResearching and understanding the mechanisms of drug resistance are essential to determine therapies that are more effective on an in...
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of only 9%. Acquired drug resistance is a major factor that limits the effectiveness of chemotherapy. Exosomes, secreted...
Addressing the antibody reproducibility crisis: A panel discussion with key scientific leaders Reproducibility and antibody validation standards are two significant challenges f...
EVENT DETAILS:DATE: May 16, 2017TIME: 9:00am PT, Noon ETThermo Fisher Scientific is proud to present the SyncD3 webinar series. As a thought-leader in science our first commit...
Much has been made in the popular press about importance of our "genes" in everything from our weight, intelligence, and our risk of disease. While there is a scientific basis...
Opens in a new windowOpens an external siteOpens an external site in a new window